ClinVar Miner

Submissions for variant NM_000518.5(HBB):c.364G>T (p.Glu122Ter) (rs33946267)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000507274 SCV000601299 pathogenic not provided 2017-02-21 criteria provided, single submitter clinical testing
Baylor Genetics RCV001004560 SCV001163642 pathogenic Hb SS disease criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV001286648 SCV001473256 pathogenic none provided 2019-08-01 criteria provided, single submitter clinical testing The HBB c.364G>T; p.Glu122Ter variant (also known as Glu121Ter when numbered from the mature protein or as Codon 121 (G->T); rs33946267) is reported in the literature in multiple individuals with clinical features varying from mild microcytic anemia to hemolytic anemia with splenomegaly and inclusion bodies (Divoka 2016, Fei 1989, Giordano 1998, Indrak 1992, Kazazian 1986, Stamatoyannopoulos 1974, Thein 1990, HbVar and references therein). In at least one severely affected individual, this variant was not found in either parent and thus appears to have arisen de novo (Kazazian 1986). The p.Glu122Ter variant was reported in early studies to segregate in several families with a dominant form of beta-thalassemia with inclusion bodies (Fei 1989, Giordano 1998, Stamatoyannopoulos 1974, Thein 1990). However, later observations in heterozygous individuals with hematology consistent with beta-thalassemia trait suggested this variant may exhibit a more typical recessive inheritance pattern, but with a clinical presentation possibly made more severe due to additional genetic or environmental factors (Divoka 2016, Giordano 1998, Indrak 1992). This variant results in a premature termination codon in the last exon of the HBB gene. While this may not lead to nonsense-mediated decay, it is expected to create a truncated protein lacking 26 amino acids, several of which are essential for heme binding (Thein 1990). Based on available information, this variant is considered to be pathogenic. References: HbVar link to p.Glu122Ter: Divoka M et al. Molecular Characterization of ß-Thalassemia in the Czech and Slovak Populations: Mediterranean, Asian and Unique Mutations. Hemoglobin. 2016 Jun;40(3):156-62. Fei YJ et al. One form of inclusion body beta-thalassemia is due to a GAA----TAA mutation at codon 121 of the beta chain. Blood. 1989 Mar;73(4):1075-7. Giordano PC et al. Phenotype variability of the dominant beta-thalassemia induced in four Dutch families by the rare cd121 (G-->T) mutation. Ann Hematol. 1998 Dec;77(6):249-55. Indrak K et al. Molecular characterization of beta-thalassemia in Czechoslovakia. Hum Genet. 1992 Feb;88(4):399-404. Kazazian HH Jr et al. Characterization of a spontaneous mutation to a beta-thalassemia allele. Am J Hum Genet. 1986 Jun;38(6):860-7. Stamatoyannopoulos G et al. Inclusion-body beta-thalassemia trait. A form of beta thalassemia producing clinical manifestations in simple heterozygotes. N Engl J Med. 1974 Apr 25;290(17):939-43. Thein SL et al. Molecular basis for dominantly inherited inclusion body beta-thalassemia. Proc Natl Acad Sci U S A. 1990 May;87(10):3924-8.
OMIM RCV000016658 SCV000036927 pathogenic Beta-thalassemia, dominant inclusion body type 2010-06-03 no assertion criteria provided literature only
Counsyl RCV000984185 SCV001132221 pathogenic beta Thalassemia 2018-01-30 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.